Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Voxelotor for Neurocognitive Function in Pediatric Sickle Cell Disease
NCT05228834Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Jun 2022
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in sickle cell disease (SCD) comparing Voxelotor Arm with Placebo Arm (2 arms). Primary endpoint: Executive Abilities Composite Score Assessed Using NIH Toolbox Cognition Module at 12 weeks. Started Jun 2022; status: terminated.
02
Drugs
voxelotor
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT05228834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05228834.